IQVIA (IQV): Reassessing Valuation After Earnings and EPS Beat Against Consensus Estimates

Simply Wall St.12-05

IQVIA Holdings (IQV) just posted quarterly results that cleared the bar on both revenue and earnings, with organic growth and helpful currency shifts pushing sales up 5.2% and adjusted EPS up 6% year ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2589397558?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/137473239-main-header/1756256222159","is_english":true,"pubTime":"2025-12-05 00:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2589397558","market":"us","top_or_hot":-1,"title":"IQVIA (IQV): Reassessing Valuation After Earnings and EPS Beat Against Consensus Estimates","media":"Simply Wall St.","content":"<div>\n<p>IQVIA Holdings (IQV) just posted quarterly results that cleared the bar on both revenue and earnings, with organic growth and helpful currency shifts pushing sales up 5.2% and adjusted EPS up 6% year ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-iqv/iqvia-holdings/news/iqvia-iqv-reassessing-valuation-after-earnings-and-eps-beat\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IQVIA (IQV): Reassessing Valuation After Earnings and EPS Beat Against Consensus Estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIQVIA (IQV): Reassessing Valuation After Earnings and EPS Beat Against Consensus Estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-05 00:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-iqv/iqvia-holdings/news/iqvia-iqv-reassessing-valuation-after-earnings-and-eps-beat><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>IQVIA Holdings (IQV) just posted quarterly results that cleared the bar on both revenue and earnings, with organic growth and helpful currency shifts pushing sales up 5.2% and adjusted EPS up 6% year ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-iqv/iqvia-holdings/news/iqvia-iqv-reassessing-valuation-after-earnings-and-eps-beat\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IQV","symbol_name":"艾昆纬","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-iqv/iqvia-holdings/news/iqvia-iqv-reassessing-valuation-after-earnings-and-eps-beat","article_id":"2589397558","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/137473239-main-header/1756256222159"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-iqv/iqvia-holdings/news/iqvia-iqv-reassessing-valuation-after-earnings-and-eps-beat","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2589397558","pubTimestamp":1764864945,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"IQVIA Holdings (IQV) just posted quarterly results that cleared the bar on both revenue and earnings, with organic growth and helpful currency shifts pushing sales up 5.2% and adjusted EPS up 6% year over year.\nSee our latest analysis for IQVIA Holdings.\nThose solid quarterly beats come on top of a strong run, with IQVIA’s share price up a robust 23.45% over the past three months and its 11.85% one year total shareholder return pointing to gradually improving sentiment rather than euphoric...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"IQV":"艾昆纬"},"translate_title":"IQVIA(IQV)：盈利和每股收益超出普遍预期后重新评估估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IQV":1.5},"content_text":"IQVIA Holdings (IQV) just posted quarterly results that cleared the bar on both revenue and earnings, with organic growth and helpful currency shifts pushing sales up 5.2% and adjusted EPS up 6% year over year. See our latest analysis for IQVIA Holdings. Those solid quarterly beats come on top of a strong run, with IQVIA’s share price up a robust 23.45% over the past three months and its 11.85% one year total shareholder return pointing to gradually improving sentiment rather than euphoric momentum. If this earnings surprise has you thinking about what else is working in life sciences, it could be a good moment to explore healthcare stocks for more ideas. With revenue and earnings still climbing, the stock trading about 10% below analyst targets, and intrinsic value models hinting at a larger discount, is IQVIA a genuine value opportunity or is the market already pricing in years of growth? AdvertisementMost Popular Narrative Narrative: 8.2% Undervalued With IQVIA last closing at $227.24 versus a narrative fair value of $247.50, the story leans toward upside if the long range forecasts land.  Continued investment in and deployment of proprietary platforms and agentic AI solutions, coupled with strategic collaborations and industry recognitions, increase switching costs and provide competitive barriers, positioning IQVIA to capture greater market share and support long-term revenue growth and margin improvement.  Read the complete narrative. Curious how steady, mid single digit growth expectations can still justify a richer future earnings multiple and rising margins? The narrative leans on a powerful mix of backlog strength, disciplined share count reduction, and a profitability upgrade that reshapes IQVIA's long term earnings base. Want to see exactly how those moving parts stack up into that fair value? Result: Fair Value of $247.50 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, a tougher CRO pricing environment and high leverage could pressure margins and limit flexibility, which could quickly undermine the upbeat earnings and valuation narrative. Find out about the key risks to this IQVIA Holdings narrative.  Build Your Own IQVIA Holdings Narrative If you would rather dig into the numbers yourself and shape a different storyline, you can build a custom view in just a few minutes, Do it your way. A great starting point for your IQVIA Holdings research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision. Ready for more smart stock ideas? Before markets move on without you, tap into fresh opportunities across sectors using the Simply Wall St Screener and line up your next potential winners today.  Secure potential growth and downside protection by targeting companies with steady cash flows and compelling valuations through these 915 undervalued stocks based on cash flows that might not stay cheap for long. Capitalize on breakthrough automation and data intelligence trends by zeroing in on innovators driving healthcare transformation with these 30 healthcare AI stocks before the crowd catches on. Boost your portfolio income by focusing on reliable payers that show both yield and resilience using these 14 dividend stocks with yields > 3% to spot candidates for long term compounding.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2589397558","isCrawlerRequest":true}